Apimeds Pharmaceuticals US Overview
Latest ROE for Apimeds Pharmaceuticals US: -32.14% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-32.14%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Apimeds Pharmaceuticals US (APUS) currently reports a ROE of -32.14%. That is below the sector sector average of -4.03%. Use the charts on this page to explore Apimeds Pharmaceuticals US's ROE history and peer comparisons.
Apimeds Pharmaceuticals US's ROE of -32.14% is lower than the its sector sector average of -4.03%. That is roughly 698.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Apimeds Pharmaceuticals US's current -32.14% should be judged against industry norms (sector average: -4.03%) and against APUS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -32.14%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -4.03%. From there, open related valuation or income-statement pages for Apimeds Pharmaceuticals US, and consider following APUS for alerts when major investors trade the stock.
